{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:32:48Z","timestamp":1785522768790,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, characterized by complex pathogenesis and immune escape mechanisms. The tumor immune microenvironment plays an increasingly recognized role in tumorigenesis, progression, and treatment. Receptor-interacting serine\/threonine-protein kinase 2 (Ripk2) plays a pivotal role in inflammatory responses and immune regulation. This study aimed to investigate the role of Ripk2 in the HCC immune microenvironment, particularly its impact on macrophage function, using a macrophage Ripk2 knockout mouse model (Ripk2\n                    <jats:sup>\n                      <jats:italic>CKO<\/jats:italic>\n                    <\/jats:sup>\n                    ), single-cell sequencing analysis (scRNA-seq) and flow cytometry (FCM). We found that inhibiting or deleting Ripk2 altered the intratumoral microbiota within macrophages, significantly increasing the abundance of\n                    <jats:italic>Streptomyces collinus<\/jats:italic>\n                    (\n                    <jats:italic>Sc<\/jats:italic>\n                    ). This alteration not only prompted a metabolic shift in macrophages but also significantly upregulated the transcription factor Myb expression, promoting Cxcl9 secretion, thereby enhancing CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell infiltration, activity, and proliferation. Furthermore, Ripk2 was found to promote lactate production\n                    <jats:italic>via<\/jats:italic>\n                    the Pax5\/Adpgk pathway, leading to CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell dysfunction and forming an immunosuppressive feedback loop in HCC. Combining a Ripk2 inhibitor (GSK583) with a PD-1\/PD-L1 inhibitor (BMS202) reduced the hepatotoxicity of BMS202 monotherapy and improved therapeutic efficacy. In conclusion, this study provides new insights into the role of Ripk2 in the HCC immune microenvironment and lays an experimental foundation for the development of Ripk2-targeted immunotherapy strategies.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08849-0","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:14:44Z","timestamp":1780028084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ripk2 promotes CD8+ T cell inactivation and hepatocellular carcinoma progression through Myb\/Cxcl9 and Pax5\/Adpgk signaling pathways"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0793-1361","authenticated-orcid":false,"given":"Zengbin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huahui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3350-2210","authenticated-orcid":false,"given":"Zhuting","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"8849_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112443","volume":"145","author":"J Chen","year":"2022","unstructured":"Chen J, Li T, Liang J, Huang Q, Huang JD, Ke Y, et al. Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy. Biomed Pharmacother. 2022;145:112443.","journal-title":"Biomed Pharmacother"},{"key":"8849_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105966","volume":"174","author":"Y Chen","year":"2021","unstructured":"Chen Y, Liu B, Wei Y, Kuang DM. Influence of gut and intratumoral microbiota on the immune microenvironment and anti-cancer therapy. Pharmacol Res. 2021;174:105966.","journal-title":"Pharmacol Res"},{"key":"8849_CR3","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41590-018-0188-x","volume":"19","author":"S He","year":"2018","unstructured":"He S, Wang X. RIP kinases as modulators of inflammation and immunity. Nat Immunol. 2018;19:912\u201322.","journal-title":"Nat Immunol"},{"key":"8849_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.650403","volume":"12","author":"H Honjo","year":"2021","unstructured":"Honjo H, Watanabe T, Kamata K, Minaga K, Kudo M. RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases. Front Pharmacol. 2021;12:650403.","journal-title":"Front Pharmacol"},{"key":"8849_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111494","volume":"128","author":"M Jiang","year":"2024","unstructured":"Jiang M, Wang D, Su N, Lou W, Chen Y, Yang H, et al. TRIM65 knockout inhibits the development of HCC by polarization tumor-associated macrophages towards M1 phenotype via JAK1\/STAT1 signaling pathway. Int Immunopharmacol. 2024;128:111494.","journal-title":"Int Immunopharmacol"},{"key":"8849_CR6","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/gutjnl-2021-324170","volume":"71","author":"N Liu","year":"2022","unstructured":"Liu N, Wang X, Steer CJ, Song G. MicroRNA-206 promotes the recruitment of CD8(+) T cells by driving M1 polarisation of Kupffer cells. Gut. 2022;71:1642\u201355.","journal-title":"Gut"},{"key":"8849_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2023.109566","volume":"125","author":"L Tian","year":"2024","unstructured":"Tian L, Zuoqin D, Jiaqi W, Xiaomeng J, Xin D, Yan Y, et al. Obesity phenotype induced by high-fat diet promotes diethylnitrosamine (DEN)-induced precancerous lesions by M1 macrophage polarization in mice liver. J Nutr Biochem. 2024;125:109566.","journal-title":"J Nutr Biochem"},{"key":"8849_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s10020-022-00475-8","volume":"28","author":"J Song","year":"2022","unstructured":"Song J, Yang R, Wei R, Du Y, He P, Liu X. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction. Mol Med. 2022;28:47.","journal-title":"Mol Med"},{"key":"8849_CR9","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1158\/1535-7163.MCT-19-0903","volume":"19","author":"C Maloney","year":"2020","unstructured":"Maloney C, Kallis MP, Edelman M, Tzanavaris C, Lesser M, Soffer SZ, et al. Gefitinib Inhibits Invasion and Metastasis of Osteosarcoma via Inhibition of Macrophage Receptor Interacting Serine-Threonine Kinase 2. Mol Cancer Ther. 2020;19:1340\u201350.","journal-title":"Mol Cancer Ther"},{"key":"8849_CR10","doi-asserted-by":"crossref","unstructured":"Wang Z, Pan B, Su L, Yu H, Wu X, Yao Y, et al. SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma. Cell Oncol. 2024;47:513\u201332.","DOI":"10.1007\/s13402-023-00880-z"},{"key":"8849_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, et al. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell. 2019;35:885\u2013900.e10.","journal-title":"Cancer Cell"},{"key":"8849_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.immuni.2025.02.008","volume":"58","author":"A Llibre","year":"2025","unstructured":"Llibre A, Kucuk S, Gope A, Certo M, Mauro C. Lactate: A key regulator of the immune response. Immunity. 2025;58:535\u201354.","journal-title":"Immunity"},{"key":"8849_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk7399","volume":"16","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang F, Peng D, Zhang D, Liu L, Wei J, et al. Activation and antitumor immunity of CD8(+) T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid. Sci Transl Med. 2024;16:eadk7399.","journal-title":"Sci Transl Med"},{"key":"8849_CR14","doi-asserted-by":"publisher","first-page":"e0217276","DOI":"10.1371\/journal.pone.0217276","volume":"14","author":"T Affolter","year":"2019","unstructured":"Affolter T, Llewellyn HP, Bartlett DW, Zong Q, Xia S, Torti V, et al. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS ONE. 2019;14:e0217276.","journal-title":"PLoS ONE"},{"key":"8849_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2159-8290.CD-23-0584","volume":"14","author":"W Sang","year":"2024","unstructured":"Sang W, Zhou Y, Chen H, Yu C, Dai L, Liu Z, et al. Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer. Cancer Discov. 2024;14:326\u201347.","journal-title":"Cancer Discov"},{"key":"8849_CR16","doi-asserted-by":"crossref","unstructured":"Triantafyllou E, Gudd CL, Mawhin MA, Husbyn HC, Trovato FM, Siggins MK, et al. PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury. J Clin Invest. 2021;131.","DOI":"10.1172\/JCI140196"},{"key":"8849_CR17","doi-asserted-by":"crossref","unstructured":"Chakladar J, Wong LM, Kuo SZ, Li WT, Yu MA, Chang EY, et al. The Liver Microbiome Is Implicated in Cancer Prognosis and Modulated by Alcohol and Hepatitis B. Cancers. 2020;12:1642.","DOI":"10.3390\/cancers12061642"},{"key":"8849_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133308","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023;14:1133308.","journal-title":"Front Immunol"},{"key":"8849_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1192970","volume":"14","author":"J You","year":"2023","unstructured":"You J, Wang Y, Chen H, Jin F. RIPK2: a promising target for cancer treatment. Front Pharmacol. 2023;14:1192970.","journal-title":"Front Pharmacol"},{"key":"8849_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2022.01.014","volume":"530","author":"D Nomoto","year":"2022","unstructured":"Nomoto D, Baba Y, Liu Y, Tsutsuki H, Okadome K, Harada K, et al. Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1\/RIPK2\/NF-\u03baB pathway. Cancer Lett. 2022;530:59\u201367.","journal-title":"Cancer Lett"},{"key":"8849_CR21","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/cns.13591","volume":"27","author":"YH Hu","year":"2021","unstructured":"Hu YH, Jiao BH, Wang CY, Wu JL. Regulation of temozolomide resistance in glioma cells via the RIP2\/NF-\u03baB\/MGMT pathway. CNS Neurosci Ther. 2021;27:552\u201363.","journal-title":"CNS Neurosci Ther"},{"key":"8849_CR22","doi-asserted-by":"publisher","first-page":"e94793","DOI":"10.1371\/journal.pone.0094793","volume":"9","author":"H Zhang","year":"2014","unstructured":"Zhang H, Chin AI. Role of Rip2 in development of tumor-infiltrating MDSCs and bladder cancer metastasis. PLoS ONE. 2014;9:e94793.","journal-title":"PLoS ONE"},{"key":"8849_CR23","doi-asserted-by":"crossref","unstructured":"Groeger S, Denter F, Lochnit G, Schmitz ML, Meyle J. Porphyromonas gingivalis Cell Wall Components Induce Programmed Death Ligand 1 (PD-L1) Expression on Human Oral Carcinoma Cells by a Receptor-Interacting Protein Kinase 2 (RIP2)-Dependent Mechanism. Infect Immun. 2020;88:e00051-20.","DOI":"10.1128\/IAI.00051-20"},{"key":"8849_CR24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1177\/00220345241230867","volume":"103","author":"RY Ma","year":"2024","unstructured":"Ma RY, Deng ZL, Du QY, Dai MQ, Luo YY, Liang YE, et al. Enterococcus faecalis Extracellular Vesicles Promote Apical Periodontitis. J Dent Res. 2024;103:672\u201382.","journal-title":"J Dent Res"},{"key":"8849_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ymthe.2023.12.010","volume":"32","author":"X Luan","year":"2024","unstructured":"Luan X, Lei T, Fang J, Liu X, Fu H, Li Y, et al. Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8(+) T cell activity. Mol Ther. 2024;32:469\u201389.","journal-title":"Mol Ther"},{"key":"8849_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","volume":"178","author":"E Riquelme","year":"2019","unstructured":"Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019;178:795\u2013806.e12.","journal-title":"Cell"},{"key":"8849_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100884","volume":"4","author":"C Xue","year":"2023","unstructured":"Xue C, Chu Q, Zheng Q, Yuan X, Su Y, Bao Z, et al. Current understanding of the intratumoral microbiome in various tumors. Cell Rep Med. 2023;4:100884.","journal-title":"Cell Rep Med"},{"key":"8849_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111799","volume":"131","author":"M Yue","year":"2024","unstructured":"Yue M, Li C, Li G. New advances in the study of PD-1\/PD-L1 inhibitors-induced liver injury. Int Immunopharmacol. 2024;131:111799.","journal-title":"Int Immunopharmacol"},{"key":"8849_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.156164","volume":"135","author":"Y Chen","year":"2024","unstructured":"Chen Y, Hu Q, Zhang W, Gong Q, Yan J, Wang Z, et al. Chidan Tuihuang granule modulates gut microbiota to influence NOD1\/RIPK2 pathway in cholestatic liver injury recovery. Phytomedicine. 2024;135:156164.","journal-title":"Phytomedicine"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08849-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08849-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:18:57Z","timestamp":1785518337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08849-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8849"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08849-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. This study was approved by the Ethics Committee of Fujian Cancer Hospital (Approval No. K2024-481-01) and strictly adhered to the ethical principles of the Declaration of Helsinki. All participants provided written informed consent.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"663"}}